Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC.

To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC.

We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases. Proportions of positive PET/CT results were calculated for six subgroups with increasing prostate specific antigen (PSA) levels (<0.5 ng/mL, 0.5 to <1.0 ng/mL, 1.0 to <2.0 ng/mL, 2.0 to <5.0 ng/mL, 5.0 to <10.0, ≥10.0 ng/mL). Detection rates of [(68)Ga]PSMA I&T were statistically compared with published detection rates of [(68)Ga]PSMA HBED-CC using exact Fisher's test.

Median PSA was 0.81 (range: 0.01 - 128) ng/mL. In 58/83 patients (70 %) at least one [(68)Ga]PSMA I&T positive lesion was detected. Local recurrent cancer was present in 18 patients (22 %), lymph node metastases in 29 patients (35 %), and distant metastases in 15 patients (18 %). The tumor detection rate was positively correlated with PSA levels, resulting in detection rates of 52 % (<0.5 ng/mL), 55 % (0.5 to <1.0 ng/mL), 70 % (1.0 to <2.0 ng/mL), 93 % (2.0 to <5.0 ng/mL), 100 % (5.0 to <10.0 ng/mL), and 100 % (≥10.0 ng/mL). There was no significant difference between the detection rate of [(68)Ga]PSMA I&T and published detection rates of [(68)Ga]PSMA HBED-CC (all p>0.05).

[(68)Ga]PSMA I&T PET/CT has high detection rates of recurrent prostate cancer that are comparable to [(68)Ga]PSMA HBED-CC.

European journal of nuclear medicine and molecular imaging. 2016 Jan 28 [Epub ahead of print]

Christoph Berliner, Milena Tienken, Thorsten Frenzel, Yuske Kobayashi, Annabelle Helberg, Uve Kirchner, Susanne Klutmann, Dirk Beyersdorff, Lars Budäus, Hans-Jürgen Wester, Janos Mester, Peter Bannas

Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. ., Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Ambulatory Center, Department for Radiation Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Martini-Klinik, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany., Pharmaceutical Radiochemistry, Technical University Munich, Walther-Meißner-Str. 3, 85748, Garching, Germany.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe